论文部分内容阅读
[目的]探讨两种四联方案应用在幽门螺杆菌根除失败的患者中的临床疗效及应用价值。[方法]选择我院进行幽门螺杆菌根除失败患者102例采取随机数字表法分为观察组和对照组,对照组给予以四环素为主的四联方法补救治疗,观察组采取以莫西沙星为主的四联方案补救治疗,记录治疗情况。[结果]观察组治疗总有效率为86.27%,对照组治疗总有效率为64.71%,组间对比差异有统计学意义(χ2=6.4114,P<0.05)。观察组治疗后白细胞介素-6(13.18±1.33)mg/L,白细胞介素-10(23.86±5.16)mg/L;对照组治疗后白细胞介素-6(23.16±2.47)mg/L,白细胞介素-10(14.15±4.09)mg/L,组间对比差异有统计学意义(t=25.4059、10.5315,P<0.05)。观察组幽门螺杆菌清除率78.43%,高于对照组幽门螺杆菌清除率56.86%,组间对比差异有统计学意义(χ2=5.4203,P<0.05)。2组不良反应比较差异无统计学意义(χ2=0.4435,P>0.05)。[结论]莫西沙星、雷贝拉唑、阿莫西林联合胶体果胶铋的四联方案应用在幽门螺杆菌根除失败患者中是一种有效的补救治疗方法,能够改善患者炎症状态,效果可靠,值得在临床大力推广使用。
[Objective] To investigate the clinical efficacy and application value of two quadruple programs in patients with failure of helicobacter pylori eradication. [Methods] A total of 102 patients with H. pylori eradication failure in our hospital were randomly divided into observation group and control group. The control group was treated with tetracycline-based quadruple therapy. The observation group was treated with moxifloxacin Master’s quadruple remedy treatment, record the treatment. [Results] The total effective rate of the observation group was 86.27%, while that of the control group was 64.71%. The difference between the two groups was statistically significant (χ2 = 6.4114, P <0.05). The levels of interleukin-6 (13.18 ± 1.33) mg / L and interleukin-10 (23.86 ± 5.16) mg / L in the observation group after treatment were significantly higher than those in the control group Interleukin -10 (14.15 ± 4.09) mg / L, the difference between the two groups was statistically significant (t = 25.4059,10.5315, P <0.05). The H.pylori clearance rate in the observation group was 78.43%, which was higher than that in the control group (56.86%). The difference between the two groups was statistically significant (χ2 = 5.4203, P <0.05). There was no significant difference in adverse reactions between the two groups (χ2 = 0.4435, P> 0.05). [Conclusion] The combination of moxifloxacin, rabeprazole and amoxicillin combined with colloidal bismuth pectin is an effective remedy for patients with eradication failure of Helicobacter pylori, which can improve the inflammatory status of patients and has reliable effect , It is worth promoting in clinical use.